Similarly, Wieland et al. (2018) reported oligoclonal expansions in the peripheral CD8+ TCR repertoire after pembrolizumab initiation in melanoma patients and identified the activation of tumor-infiltrating CD8+ T-cell clones in peripheral blood after anti–PD-1 immunotherapy. This evidence concerns the gene CD8A and melanoma.